Diosmin is most often used for hemorrhoids and leg sores caused by poor blood flow. It's also used for other conditions, but there's no strong evidence to support these uses.
Diosmin is often taken with hesperidin. Hesperidin is another plant chemical.
How does it work ?
Uses & Effectiveness ?
Possibly Effective for
- Hemorrhoids. Taking diosmin in high doses along with hesperidin seems to reduce symptoms of hemorrhoids. Taking diosmin in lower doses along with hesperidin plus troxerutin also seems to help. Taking diosmin in lower doses along with hesperidin seems to help prevent hemorrhoids from coming back.
- Leg sore caused by weak blood circulation (venous leg ulcer). Taking diosmin with hesperidin and using compression dressing seems to help heal leg ulcers caused by poor circulation.
Insufficient Evidence for
- Back pain. Early research shows that taking diosmin for at least 8 weeks decreases pain and might reduce the need to use rescue pain medicine similarly to receiving the standard medications mannitol and dexamethasone.
- Poor circulation that can cause the legs to swell (chronic venous insufficiency or CVI). Some research shows that taking diosmin may help to reduce pain by a small amount in people with CVI. But not all research agrees.
- Swelling in the arms or legs caused by damage to the lymph system (lymphedema). Taking diosmin with hesperidin might not reduce swelling of the arms following surgery for breast cancer.
- Minor bleeding.
- Bleeding gums.
- Bleeding (hemorrhage) in the eye.
- Preventing damage to the liver.
- Varicose veins.
- Other conditions.
Special Precautions and Warnings
Bleeding disorders: Diosmin might make bleeding disorders worse. If you have a bleeding disorder, don't use diosmin.
Chlorzoxazone (Parafon Forte, Paraflex) interacts with DIOSMIN
The body breaks down chlorzoxazone (Parafon Forte, Paraflex) to get rid of it. Diosmin might decrease how quickly the body breaks down chlorzoxazone (Parafon Forte, Paraflex). Taking diosmin along with chlorzoxazone (Parafon Forte, Paraflex) might increase the effects and side effects of chlorzoxazone (Parafon Forte, Paraflex).
Diclofenac (Voltaren, others) interacts with DIOSMIN
The body breaks down diclofenac (Voltaren, others) to get rid of it. Diosmin might decrease how quickly the body breaks down diclofenac (Voltaren, others). Taking diosmin along with diclofenac (Voltaren, others) might increase the effects and side effects of diclofenac (Voltaren, others).
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with DIOSMIN
Some medications are changed and broken down by the liver. Diosmin might decrease how quickly the liver breaks down some medications. Taking diosmin along with some medications that are broken down by the liver might increase the effects and side effects of these medications. Before taking diosmin, talk to your healthcare provider if you take any medications that are changed by the liver.
Some medications that are changed by the liver include celecoxib (Celebrex), diclofenac (Voltaren), fluvastatin (Lescol), glipizide (Glucotrol), ibuprofen (Advil, Motrin), irbesartan (Avapro), losartan (Cozaar), phenytoin (Dilantin), piroxicam (Feldene), tamoxifen (Nolvadex), tolbutamide (Tolinase), torsemide (Demadex), warfarin (Coumadin), and others.
Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates) interacts with DIOSMIN
Some medications are changed and broken down by the liver. Diosmin might decrease how quickly the liver breaks down some medications. Taking diosmin along with some medications that are broken down by the liver may increase the effects and side effects of these medications.
Some medications changed by the liver include acetaminophen, chlorzoxazone (Parafon Forte), ethanol, theophylline, and anesthetics such as enflurane (Ethrane), halothane (Fluothane), isoflurane (Forane), and methoxyflurane (Penthrane).
Medications moved by pumps in cells (P-Glycoprotein Substrates) interacts with DIOSMIN
Some medications are moved by pumps in cells. Diosmin might make these pumps less active and increase the amount of some medications that get absorbed by the body. This might increase the amount of some medications in the body, which could lead to more side effects.
Some medications that are moved by these pumps include some chemotherapeutic agents (etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir, saquinavir), H2 antagonists (cimetidine, ranitidine), some calcium channel blockers (diltiazem, verapamil), corticosteroids, erythromycin, cisapride (Propulsid), fexofenadine (Allegra), cyclosporine, loperamide (Imodium), quinidine, and others.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with DIOSMIN
Diosmin might slow blood clotting. Taking diosmin along with medications that also slow blood clotting might increase the chances of bruising and bleeding. Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.
Carbamazepine (Tegretol) interacts with DIOSMIN
The body breaks down carbamazepine (Tegretol) to get rid of it. Diosmin might decrease how quickly the body breaks down carbamazepine (Tegretol). Taking diosmin along with carbamazepine (Tegretol) might increase the effects and side effects of carbamazepine (Tegretol).
Fexofenadine (Allegra) interacts with DIOSMIN
Some medications including fexofenadine (Allegra) are moved by pumps in cells. Diosmin might make these pumps less active and increase how much of some medications get absorbed by the body. This might cause more side effects from some medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with DIOSMIN
Some medications are changed and broken down by the liver. Diosmin may decrease how quickly the liver breaks down some medications. Taking diosmin along with some medications may increase the effects and side effects of these medications. Before taking diosmin, talk to your health care provider if you are taking any medications that are changed by the liver.
Some medications changed by the liver include lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), clarithromycin (Biaxin), erythromycin, cyclosporine (Neoral, Sandimmune), amlodipine (Norvasc), verapamil (Calan, Isoptin), diltiazem (Cardizem), estrogens, indinavir (Crixivan), fexofenadine (Allegra), triazolam (Halcion), alprazolam (Xanax), and many others.
Be cautious with this combination
The following doses have been studied in scientific research:
- For hemorrhoids: For treating hemorrhoids, 1350 mg of diosmin plus 150 mg of hesperidin twice daily for 4 days followed by 900 mg of diosmin and 100 mg of hesperidin twice daily for 3 days has been used. Also, 300 mg of diosmin, 300 mg of troxerutin, and 300 mg of hesperidin three times daily for 3 days, followed by two times daily for 2 days, and then once daily for 7 days has been used. Thereafter, 300 mg of diosmin, 300 mg of troxerutin, and 100 mg of hesperidin has been used daily for one month. Some researchers also try 600 mg of diosmin three times daily for 4 days, followed by 300 mg twice daily for 10 days, in combination with 11 grams of psyllium daily. However, this lower diosmin dose does not seem to be as effective.
- For leg ulcers caused by poor circulation (venous stasis ulcers): 900 mg of diosmin plus 100 mg of hesperidin daily has been used for up to 2 months.
Hiraoka A, Kiguchi D, Ninomiya T, et al. Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation? Eur J Gastroenterol Hepatol 2019;31(7):878-84. doi: 10.1097/MEG.0000000000001368. View abstract.
Hirose S, Mitsudome A, Yasumoto S, et al. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;101:E9 (abstract). View abstract.
Hollyer T, Boon H, Georgousis A, et al. The use of CAM by women suffering from nausea and vomiting during pregnancy. BMC Comp Altern Med 2002;2:5. View abstract.
Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989;2:469-73. View abstract.
Huang H, Song L, Zhang H, Zhang H, Zhang J, Zhao W. Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis. Kidney Blood Press Res. 2013;38(1):31-41. View abstract.
Hug G, McGraw CA, Bates SR, et al. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991;119:799-802. View abstract.
Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002;13:708-14.. View abstract.
Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:380-7. View abstract.
Imbe A, Tanimoto K, Inaba Y, et al. Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps. Endocr J 2018;65(5):521-6. View abstract.
Ishikura H, Matsuo N, Matsubara M, et al. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996;20:55-8. View abstract.
Ismail AM, Hamed AH, Saso S, Thabet HH. Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2014;180:148-52. View abstract.
Jeulin C, Lewin LM. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update 1996;2:87-102. View abstract.
Bergan, J. J., Schmid-Schonbein, G. W., and Takase, S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 2001;52 Suppl 1:S43-S47. View abstract.
Buckshee, K., Takkar, D., and Aggarwal, N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997;57(2):145-151. View abstract.
Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Di Renzo, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., and Cacchio, M. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology 2005;56(1):1-8. View abstract.
Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Di Renzo, A., Ruffini, I., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cornelli, U., Hosoi, M., and Cacchio, M. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57(2):131-138. View abstract.
Cesarone, M. R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., and Corsi, M. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb.Hemost. 2006;12(2):205-212. View abstract.
Cospite, M. and Dominici, A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8(4 Suppl):61-65. View abstract.
Cypriani, B., Limasset, B., Carrie, M. L., le Doucen, C., Roussie, M., de Paulet, A. C., and Damon, M. Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils. Biochem Pharmacol 4-6-1993;45(7):1531-1535. View abstract.
Glinski, W, Chodynicka, B., Roszkiewicz, J., and et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology. 1999;14(4):151-157.
Godeberge, P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45(6 Pt 2):574-578. View abstract.
Guilhou, J. J., Fevrier, F., Debure, C., Dubeaux, D., Gillet-Terver, M. N., Guillot, B., Levesque, H., Marzin, L., Mignot, J., Ouvry, P., Pillion, G., Van, Landuyt H., Zuccarelli, F., and Nicolaides, A. N. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int.J.Microcirc.Clin.Exp. 1997;17 Suppl 1:21-26. View abstract.
Jantet, G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002;53(3):245-256. View abstract.
Jean, T. and Bodinier, M. C. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology 1994;45(6 Pt 2):554-559. View abstract.
Keenoy, B., Vertommen, J., and De, Leeuw, I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. Diabetes Nutr Metab 1999;12(4):256-263. View abstract.
Korthuis, R. J. and Gute, D. C. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc.Res 1999;36 Suppl 1:15-23. View abstract.
Smith, P. D. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc.Res 1999;36 Suppl 1:24-36. View abstract.
Struckmann, J. R. and Nicolaides, A. N. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 1994;45(6):419-428. View abstract.
Agir MS, Eraslan G. The effect of diosmin against liver damage caused by cadmium in rats. J Food Biochem. 2019;43(9):e12966. View abstract.
Akhmetzianov RV, Bredikhin RA. Clinical efficacy of conservative treatment with micronized purified flavonoid fraction in female patients with pelvic congestion syndrome. Pain Ther 2021;10(2):1567-1578. View abstract.
Attia TM. Efficacy and Safety of Daflon in the Treatment of Idiopathic Epistaxis. Am J Rhinol Allergy. 2019;33(1):62-68. View abstract.
Bagnati M, Puricelli C, Bauce G, et al. Short-term effects of supplemental L-arginine, diosmin, troxerutin, and hesperidin in diabetic patients: A Pilot Study. Biomed Res Int 2021;2021:3508281. View abstract.
Bedada SK, Boga PK, Kotakonda HK. The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. Xenobiotica. 2017;47(3):230-35. View abstract.
Bedada SK, Boga PK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879-84. View abstract.
Bedada SK, Neerati P. Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(2):115-21.View abstract.
Bogachev VY, Boldin BV, Turkin PY. Administration of micronized purified flavonoid fraction during sclerotherapy of reticular veins and telangiectasias: Results of the national, multicenter, observational program VEIN ACT PROLONGED-C1. Adv Ther. 2018l;35(7):1001-1008. View abstract.
Bozdag M, Eraslan G. The effect of diosmin against lead exposure in rats. Naunyn Schmiedebergs Arch Pharmacol. 2019. View abstract.
Burkina V, Zlabek V, Halsne R, Ropstad E, Zamaratskaia G. In vitro effects of the citrus flavonoids diosmin, naringenin and naringin on the hepatic drug-metabolizing CYP3A enzyme in human, pig, mouse and fish. Biochem Pharmacol. 2016;110-111:109-16 View abstract.
Cacchio A, Prencipe R, Bertone M, et al. Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren) in addition to complex decongestive therapy on management of breast cancer-related lymphedema. Support Care Cancer. 2019;27(4):1471-1480. View abstract.
Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566-73. View abstract.
Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70:491-9. View abstract.
Danielsson G, Jungbeck C, Peterson K, Norgren L. A randomised controlled trial of micronized purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 2002;23(1):73-6. View abstract.
Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65:337-53. View abstract.
Feldo M, Wójciak-Kosior M, Sowa I, et al. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules. 2019;24(18). pii: E3316. View abstract.
Gavrilov SG, Karalkin AV, Moskalenko YP, Grishenkova AS. Efficacy of two micronized purified flavonoid fraction dosing regimens in the pelvic venous pain relief. Int Angiol. 2021;40(3):180-186. View abstract.
Giannini I, Amato A, Basso L, Tricomi N, Marranci M, Pecorella G, Tafuri S, Pennisi D, Altomare DF. Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial. Tech Coloproctol. 2015 Jun;19(6):339-45. View abstract.
Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85.. View abstract.
Ho Y, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids. Dis Colon Rectum 2000;43:66-9. View abstract.
Khryshchanovich VY, Nebylitsin YS, Kosinets VA. Efficacy of micronized purified flavonoid fraction-based venoactive therapy after endovenous mechanochemical obliteration: Prospective comparative study. Drugs Real World Outcomes. 2021. View abstract.
Kumar RM, Van Gompel JJ, Bower R, Rabinstein AA. Spontaneous intraventricular hemorrhage associated with prolonged diosmin therapy. Neurocrit Care. 2011 Jun;14(3):438-40. View abstract.
Li T, Zhu W, Liu G, Fang C, Quan S. Diosmin for the prevention of ovarian hyperstimulation syndrome. Int J Gynaecol Obstet. 2020;149(2):166-170. View abstract.
Middleton E. Some biological properties of plant flavonoids. Ann Allergy 1988;61:53-7. View abstract.
Milano G, Leone S, Fucile C, Zuccoli ML, Stimamiglio A, Martelli A, Mattioli F. Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports. J Med Case Rep. 2014 Jun 16;8:194. View abstract.
Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surgery 2000;87:868-72. View abstract.
Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997;48:93-8.. View abstract.
Poór M, Boda G, Mohos V, et al. Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin. Biomed Pharmacother. 2018;102:912-921. View abstract.
Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428-36. View abstract.
Rajnarayana K, Venkatesham A, Krishna DR. Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers. Drug Metabol Drug Interact. 2007;22(2-3):165-74. View abstract.
Rajnarayana K, Venkatesham A, Nagulu M, Srinivas M, Krishna DR. Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers. Drug Metabol Drug Interact. 2008;23(3-4):311-21. View abstract.
Rizk, S. M and Sabri, N. A. Evaluation of Clinical Activity and Safety of Dalfon® 500mg in Type 2 Diabetic Femal Patients. Saudi Pharmacetical Journal 3-17-2009;199-209.
Russo R, Chandradhara D, De Tommasi N. Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers. Molecules. 2018;23(9). pii: E2174. View abstract.
Sahin A, Kutluhan MA, Yildirim C, Urkmez A, Akan S, Verit A. Results of purified micronized flavonoid fraction in the treatment of categorized type III chronic pelvic pain syndrome: a randomized controlled trial. Aging Male. 2020;23(5):1103-1108. View abstract.
Schastlivtsev I, Lobastov K, Barinov V, Kanzafarova I. Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study. Int Angiol. 2020;39(5):361-371. View abstract.
Serra R, Ielapi N, Bitonti et al. Efficacy of a low-dose diosmin therapy on improving symptoms and quality of life in patients with chronic venous disease: Randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(3):999. View abstract.
Sheikh P, Lohsiriwat V, Shelygin Y. Micronized purified flavonoid fraction in hemorrhoid disease: A systematic review and meta-analysis. Adv Ther. 2020;37(6):2792-2812. View abstract.
Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 2012;52(1):182-90. View abstract.
Sirlak M, Akar AR, Eryilmaz S, et al. Micronized purified flavonoid fraction in pretreating CABG patients. Tex Heart Inst J. 2010;37(2):172-7. View abstract.
Steinbruch M, Nunes C, Gama R, et al. Is nonmicronized diosmin 600?mg as effective as micronized diosmin 900?mg plus hesperidin 100?mg on chronic venous disease symptoms? Results of a noninferiority study. Int J Vasc Med. 2020;2020:4237204. View abstract.
Thanapongsathorn W, Vajrabukka T. Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids. Dis Colon Rectum 1992;35:1085-8. View abstract.
Villa P, Cova D, De Francesco L, et al. Protective effect of diosmetin on in vitro cell membrane damage and oxidative stress in cultured rat hepatocytes. Toxicology 1992;73:179-89. View abstract.
Wang Y, Fang X, Ye L, Li Y, Shi H, Cao Y. A Randomized Controlled Trial Evaluating the Effects of Diosmin in the Treatment of Radicular Pain. Biomed Res Int. 2017;2017:6875968. View abstract.
Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem. 2007 Sep 5;55(18):7620-5. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.